Richard Lipton, MD: Eptinezumab Maintains Reductions in the Impact of Migraine
The director of the Montefiore Headache Center and professor of neurology at Albert Einstein College of Medicine spoke about the results of an analysis of eptinezumab’s effect on the severity of migraine and its impact on patients’ lives.
By: Richard Lipton, MD
Published: July 13, 2019
“The findings of this study are really good news both for patients and physicians because they say that, over the course of a month, the impact of migraine on patients’ lives, as measured by HIT-6, reduces very steeply and then stays reduced through the treatment period.”
At the 2019 American Headache Society Annual Meeting, July 11-14, in Philadelphia, Pennsylvania, a number of presentations and posters revealed data regarding eptinezumab’s impact on patients with migraine. The anti-calcitonin gene-related peptide (CGRP) therapy has shown promise thus far in reducing the frequency of headache attacks in these patients, but these new data suggest that the Alder Biopharmaceuticals agent may also reduce the impact migraine has on these individuals’ lives.
Richard Lipton, MD, director, Montefiore Headache Center, and professor of neurology, Albert Einstein College of Medicine, was involved in a number of these studies, including one which focused specifically on the impact of migraine as measured by the 6-item Headache Impact Test (HIT-6) questionnaire.1 The HIT-6 questionnaire, while easy to implement in practice, has also had its usefulness in migraine clarified in recent works.2,3 Using this test, Lipton and colleagues explored eptinezumab’s effect on patients’ scores.
Ultimately, while conducting this subanalysis of the PROMISE-2 study, Lipton and colleagues found that the treatment not only drastically lowered the impact migraine was having on patients, it allowed them to maintain this reduction over the full 6-month treatment period, with some significant reductions seen as early as month 1. To find out more about these findings, NeurologyLive® sat with Lipton at the meeting.
For more coverage of AHS 2019, click here.REFERENCES
1. Lipton R. Eptinezumab Demonstrated Early and Sustained Reductions in HIT-6 Total Score Over Time in Patients with Chronic Migraine in the PROMISE-2 Trial. Presented at: 2019 American Headache Society Annual Meeting; July 11-14, 2019; Philadelphia, PA. Poster 215LB
2. Houts C. Content validity of the HIT-6 in migraine patients: results of a systematic literature review. Presented at: 2019 American Headache Society Annual Meeting; July 11-14, 2019; Philadelphia, PA. Poster 213LB.
3.. Cady R. Chronic migraine: Establishing a responder definition for the HIT-6 total score. Presented at: 2019 American Headache Society Annual Meeting; July 11-14, 2019; Philadelphia, PA. 214LB.